Study to Assess the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder
Phase
3Span
132 weeksSponsor
Neumora Therapeutics, Inc.Inwood, New York
Recruiting
Study to Assess the Safety and Effectiveness of NMRA-335140-501
Phase
3Span
190 weeksSponsor
Neumora Therapeutics, Inc.Inwood, New York
Recruiting
Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)
Phase
3Span
290 weeksSponsor
Merck Sharp & Dohme LLCInwood, New York
Recruiting
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
Phase
3Span
236 weeksSponsor
Boehringer IngelheimInwood, New York
Recruiting
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
Phase
3Span
376 weeksSponsor
Boehringer IngelheimInwood, New York
Recruiting
1-5 of 5